ProCE Banner Activity

Discordance in Management of Adverse Events Associated With Oral Therapies in Hormone Receptor–Positive Breast Cancer Among Healthcare Professionals and Experts: Findings From an Online Decision Support Tool

PDF

This poster, presented at ASCO Quality Care 2022, features an analysis of responses entered by healthcare professionals into an online treatment decision support tool for management of adverse events associated with CDK4/6, PI3K, and mTOR inhibitors in hormone receptor–positive breast cancer.

Released: October 03, 2022

Expiration: October 02, 2023

Share

Additional Information

Contact:

Kristen Rosenthal, PhD

Associate Director,

Scientific Services

Clinical Care Options

Telephone: 855.224.2241

krosenthal@clinicaloptions.com